Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blisibimod Long-term Safety Extension in SLE
NCT01305746Phase 2Completed
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Apr 2011
- Primary completion
- Jul 2013
- Modality
- Fc-Fusion Proteins
- Countries
- 11
01
Overview
A Phase 2 trial of blisibimod in systemic lupus erythematosus (SLE), sponsored by Anthera Pharmaceuticals, Inc.. Started Apr 2011; status: completed.
02
Drugs
blisibimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01305746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01305746.